Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2016 (← Previous) (Next →)

Filing Date: Jul 28, 2016

Total Value: $98.67B (100.0% shares, 0.0% debt)

Holdings (5)

GKOS Glaukos Corporation 76.5%

Value $75.44B Shares 2,586,985 Est. Cost $30.09 Unrealized -23.1%

OCUL Ocular Therapeutix, Inc. 11.1%

Value $10.97B Shares 2,215,384 Est. Cost $20.09 Unrealized -50.7%

— Clovis Oncology, Inc. 5.7%

Value $5.59B Shares 407,416 Est. Cost $56000.00 Unrealized —

— Achaogen, Inc. 4.9%

Value $4.856B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— CymaBay Therapeutics, Inc. 1.8%

Value $1.825B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GKOS	Glaukos Corporation	2,586,985	$75.44B	76.5%	$30.09	-23.1%	Common Stock	377322102
OCUL	Ocular Therapeutix, Inc.	2,215,384	$10.97B	11.1%	$20.09	-50.7%	Common Stock	67576A100
—	Clovis Oncology, Inc.	407,416	$5.59B	5.7%	$56000.00	—	Common Stock	189464100
—	Achaogen, Inc.	1,281,152	$4.856B	4.9%	$13050.00	—	Common Stock	004449104
—	CymaBay Therapeutics, Inc.	1,048,601	$1.825B	1.8%	$9830.00	—	Common Stock	23257D103